Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Alzheimer´s Disease

In brief

The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD). In the study participants receive increasing dose of active treatment (250mg vs 500mg vs 750mg) or matched placebo in the form of tablets BID.

Key facts

Study ID

NCT07741526

Run by

Arctic Therapeutics

People needed

33

Starts

2025-10-14

Expected to finish

2027-05-31

Last updated by the study team

2026-08-03

Who can join

Age: 50 and older, up to 84. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has provided informed consent for participation in trial.
• Subject is male or female, aged 50 or older but younger than 85.
• Female Subjects:
• Of child-bearing potential in the age range of 50-60 years who are still menstruating, are willing to perform a pregnancy test at screening visit, V1 (Baseline) and at each subsequent visit and adhere to contraception requirements.
• Of nonchildbearing Potential (WONCBP), women in the following categories are considered WONCBP: Premenopausal female permanently sterile due to one of the following (for the purpose of this study): Women who have documented hysterectomy, documented bilateral salpingectomy, documented bilateral oophorectomy
• Postmenopausal female is defined as no menses for 12 months. If confirmation is needed, a high follicle stimulating hormone (FSH) level in the postmenopausal range will be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). Females on HRT and whose menopausal status is in doubt must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
• Male subjects:
• Male subjects with female partners of child-bearing potential who are willing or able to adhere to contraception requirements, or male subjects with documented infertility.
• Subject has MCI or mild dementia due to Alzheimer´s disease according to Jack 2024 with a CDR of 0.5 or 1.0 receiving standard AD care (SOC) (65).
• Subject has an MMSE score of >21 < 28
• Subject is willing to have a baseline and follow up blood tests according to the schedule of assessments, for up to 12 months.
• Subject has a pTau 217 value of > 0.35 pg/ml
• Subject is willing and able to undergo MRI, and amyloid PET scan evaluations of the brain, which fulfill the following requirements:
• PET amyloid brain load >32 centiloids
• MRI <8 micro bleeds
• Subject has a spouse/close relative/caregiver as study partner who lives with him/her or supervises subject care. The caregiver must be willing to accompany the subject to all study visits and able to give informed consent for their own participation and be able to read and write.
• If taking concomitant medications, treated with stable doses of drugs essentially required for chronic medical conditions which do not lead to exclusion, during a period of at least 3 months prior to screening, and dose regimen is expected to remain stable during the conduct of the study.
• Subject is able to read, write, speak clearly for the cognitive tests, with eyesight and hearing sufficient to enable completion of the cognitive tests.

You may not qualify if…

• Subject has MRI evidence evaluated by central read of
• Brain abnormality caused by other neurological disease than AD including but not limited to vascular disease (vascular dementia), acute or subacute cerebral hemorrhage, large-vessel stroke, brain tumors, inflammatory immunological or metabolic disorders.
• More than 7 microbleeds, multiple lacunes or any lacune in strategically important location, Grade 2 and 3 white matter lesions, any focal area of superficial siderosis or medical implants or foreign bodies unsuitable for MRI.
• Subject has moderate or severe dementia, defined as CDR of ≥ 2.0
• Subject has clinically significant illness, mental or physical, that, in the opinion of the investigator, might confound the results of the study, pose additional risk to the Subject by their participation, or prevent/impede the subject from completing the study.
• Subject has known sensitivity to NAC/NACA.
• Known or recently suspected (3 months) excessive alcohol or drug abuse.
• History of liver disease.
• There is any concern by the investigator regarding the subject's safety, compliance, or suitability with respect to his/her participation in the study.
• Use of NAC or other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 14 days, whichever is longer.
• Subjects who are or have been on AD immunotherapy.
• Any suicidal ideation or suicidal behavior in the C-SSRS (C-SSRS score > 0)

Where it is running

• Sanos Clinic Gandrup — Gandrup, Denmark
• Sanos Clinic Herlev — Herlev, Denmark
• Sanos Clinic Vejle — Vejle, Denmark
• Landspitali University Hospital — Reykjavik, Iceland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.